LV10684B - Controlled release preparation containing a salt of morphine - Google Patents

Controlled release preparation containing a salt of morphine

Info

Publication number
LV10684B
LV10684B LVP-94-228A LV940228A LV10684B LV 10684 B LV10684 B LV 10684B LV 940228 A LV940228 A LV 940228A LV 10684 B LV10684 B LV 10684B
Authority
LV
Latvia
Prior art keywords
morphine
salt
controlled release
preparations
manufacture
Prior art date
Application number
LVP-94-228A
Other languages
English (en)
Other versions
LV10684A (lv
Inventor
Birgitta Olsson
Maritta Anneli Chefrad
Gert Ragnarsson
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20389415&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV10684(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of LV10684A publication Critical patent/LV10684A/xx
Publication of LV10684B publication Critical patent/LV10684B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
LVP-94-228A 1993-03-30 1994-11-30 Controlled release preparation containing a salt of morphine LV10684B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9301057A SE9301057L (sv) 1993-03-30 1993-03-30 Beredning med kontrollerad frisättning
PCT/SE1994/000264 WO1994022431A1 (fr) 1993-03-30 1994-03-24 Preparation a liberation controlee contenant un sel de morphine

Publications (2)

Publication Number Publication Date
LV10684A LV10684A (lv) 1995-06-20
LV10684B true LV10684B (en) 1996-02-20

Family

ID=20389415

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-94-228A LV10684B (en) 1993-03-30 1994-11-30 Controlled release preparation containing a salt of morphine

Country Status (25)

Country Link
US (1) US5614218A (fr)
EP (1) EP0642335B2 (fr)
JP (1) JP4107678B2 (fr)
KR (1) KR100316206B1 (fr)
CN (1) CN1104891C (fr)
AT (1) ATE189771T1 (fr)
AU (1) AU680891C (fr)
CA (1) CA2135639C (fr)
CZ (1) CZ284924B6 (fr)
DE (1) DE69423028T3 (fr)
DK (1) DK0642335T4 (fr)
EE (1) EE03147B1 (fr)
ES (1) ES2144516T5 (fr)
FI (1) FI113743B (fr)
GR (1) GR3033325T3 (fr)
HU (1) HU227344B1 (fr)
LV (1) LV10684B (fr)
NO (1) NO310015B1 (fr)
NZ (1) NZ263632A (fr)
PL (1) PL175326B1 (fr)
PT (1) PT642335E (fr)
RU (1) RU2136283C1 (fr)
SE (1) SE9301057L (fr)
SK (1) SK280362B6 (fr)
WO (1) WO1994022431A1 (fr)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
AU735113C (en) * 1991-12-24 2007-06-14 Mundipharma Medical Gmbh Opioid formulations for treating pain
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
IL109460A (en) * 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
IL109944A (en) † 1993-07-01 1998-12-06 Euro Celtique Sa Continuous release dosage form containing morphine and a method of preparing such sustained release unit dosage forms
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
DE19607395C2 (de) * 1996-02-28 2002-11-21 Lohmann Therapie Syst Lts Salze aus einem kationischen narkotischen Analgetikum mit einem anionischen nichtnarkotischen Analgetikum, Verfahren zu deren Herstellung und die diese Salze enthaltenden pharmazeutischen Präparate
US6245351B1 (en) 1996-03-07 2001-06-12 Takeda Chemical Industries, Ltd. Controlled-release composition
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6066339A (en) * 1997-10-17 2000-05-23 Elan Corporation, Plc Oral morphine multiparticulate formulation
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
FR2794646B1 (fr) 1999-06-09 2001-09-21 Ethypharm Lab Prod Ethiques Microgranules de sulfate de morphine, procede de preparation et composition les contenant
KR20020059653A (ko) 1999-10-29 2002-07-13 그린 마틴, 브라이언 쥐 테슬리 서방성 하이드로코돈 제형
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
JP2004512354A (ja) 2000-10-30 2004-04-22 ユーロ−セルティーク，エス．エイ． ヒドロコドン放出制御製剤
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
AU4061702A (en) * 2001-05-15 2003-04-03 Mcneil-Ppc, Inc. Dip coating compositions containing starch or dextrin
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US20030072731A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing starch or dextrin
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
US8309118B2 (en) * 2001-09-28 2012-11-13 Mcneil-Ppc, Inc. Film forming compositions containing sucralose
AU2003225837B2 (en) * 2002-03-15 2008-11-06 Forest Laboratories Holdings Limited NE and 5-HT reuptake inhibitors for treating visceral pain syndromes
US7429619B2 (en) * 2002-08-02 2008-09-30 Mcneil Consumer Healthcare Polyacrylic film forming compositions
US7815934B2 (en) * 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
AU2003272601B2 (en) * 2002-09-20 2009-05-07 Alpharma Pharmaceuticals, Llc Sustained-release opioid formulations and methods of use
EP1546120A4 (fr) * 2002-10-04 2006-11-22 Pharmacia Corp Compositions pharmaceutiques pour le traitement de la maladie de parkinson
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040132826A1 (en) * 2002-10-25 2004-07-08 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
WO2004067039A1 (fr) * 2003-01-28 2004-08-12 Collegium Pharmaceutical, Inc. Compositions multiparticulaires de milnacipran destinees a etre administrees par voie orale
US8877241B2 (en) 2003-03-26 2014-11-04 Egalet Ltd. Morphine controlled release system
TWI347201B (en) * 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
ES2336913T3 (es) * 2003-08-08 2010-04-19 Biovail Laboratories International Srl Comprimido de liberacion modificada de hidrocloruro de bupropion.
EP1810678A1 (fr) 2006-01-19 2007-07-25 Holger Lars Hermann Utilisation de morphine et naloxone pour la substitution de médicaments
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US20080069871A1 (en) * 2006-07-21 2008-03-20 Vaughn Jason M Hydrophobic abuse deterrent delivery system
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
EP2155167A2 (fr) 2007-06-04 2010-02-24 Egalet A/S Compositions pharmaceutiques à libération contrôlée pour un effet prolongé
JP5965583B2 (ja) 2007-08-13 2016-08-10 インスピリオン デリバリー テクノロジーズ エルエルシー 乱用抵抗性医薬組成物、その使用方法および作製方法
GB2462022B (en) * 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
AU2010211220B2 (en) 2009-02-06 2013-08-01 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
DK3045043T3 (da) 2009-02-26 2020-08-03 Relmada Therapeutics Inc Orale farmaceutiske sammensætninger af 3-hydroxy-n-methylmorphinan med forlænget frigivelse og fremgangsmåde til anvendelse
EP2445487A2 (fr) 2009-06-24 2012-05-02 Egalet Ltd. Formulations à libération contrôlée
CA2798702A1 (fr) 2010-05-11 2011-11-17 Cima Labs Inc. Formes dosifiees orales a liberation prolongee contenant du metoprolol resistantes aux alcools
MX2013000024A (es) 2010-07-06 2013-02-01 Gruenenthal Gmbh Nuevas formas de dosificacion gastrorretentivas.
EA201590165A1 (ru) 2012-07-06 2015-08-31 Эгалет Лтд. Сдерживающие злоупотребление фармацевтические композиции для контролируемого высвобождения
CA2907428A1 (fr) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Compositions anti-abus et methodes d'utilisation
WO2015023675A2 (fr) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Comprimé extrudé anti-abus à libération immédiate
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
EP3209282A4 (fr) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Forme galénique anti-abus de remplissage de liquide à libération prolongée

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK150008C (da) * 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
CA2007181C (fr) * 1989-01-06 1998-11-24 Angelo Mario Morella Compose pharmaceutique a liberation continue
SE8902699D0 (sv) * 1989-08-09 1989-08-09 Lejus Medical Ab Diltiazem containing pharmaceutical compositios
DE4105480A1 (de) * 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
US5273760A (en) † 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5478577A (en) † 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
SE9202250D0 (sv) * 1992-07-29 1992-07-29 Gacell Lab Ab Controlled release morphine preparation

Also Published As

Publication number Publication date
CA2135639A1 (fr) 1994-10-13
CZ284924B6 (cs) 1999-04-14
DE69423028D1 (de) 2000-03-23
EE03147B1 (et) 1999-02-15
DE69423028T3 (de) 2006-07-20
SE9301057D0 (sv) 1993-03-30
NO944565L (no) 1994-11-29
JPH08501319A (ja) 1996-02-13
NZ263632A (en) 1997-06-24
EP0642335B1 (fr) 2000-02-16
HU9403437D0 (en) 1995-02-28
FI945621A0 (fi) 1994-11-29
HUT71417A (en) 1995-11-28
DE69423028T2 (de) 2001-01-18
PL175326B1 (pl) 1998-12-31
CN1104891C (zh) 2003-04-09
RU94046147A (ru) 1996-11-10
SE9301057L (sv) 1994-10-01
NO310015B1 (no) 2001-05-07
AU680891C (en) 2002-01-03
NO944565D0 (no) 1994-11-29
DK0642335T3 (da) 2000-07-24
CA2135639C (fr) 2006-02-07
SK280362B6 (sk) 1999-12-10
KR100316206B1 (ko) 2002-11-09
LV10684A (lv) 1995-06-20
ES2144516T5 (es) 2005-07-01
US5614218A (en) 1997-03-25
FI113743B (fi) 2004-06-15
CZ298694A3 (en) 1995-05-17
PT642335E (pt) 2000-08-31
FI945621A (fi) 1994-11-29
SK143794A3 (en) 1995-06-07
RU2136283C1 (ru) 1999-09-10
DK0642335T4 (da) 2005-05-23
AU680891B2 (en) 1997-08-14
JP4107678B2 (ja) 2008-06-25
CN1106608A (zh) 1995-08-09
ES2144516T3 (es) 2000-06-16
AU6439394A (en) 1994-10-24
GR3033325T3 (en) 2000-09-29
EP0642335A1 (fr) 1995-03-15
PL306421A1 (en) 1995-04-03
WO1994022431A1 (fr) 1994-10-13
EP0642335B2 (fr) 2005-01-19
HU227344B1 (en) 2011-04-28
ATE189771T1 (de) 2000-03-15

Similar Documents

Publication Publication Date Title
GR3033325T3 (en) Controlled release preparation containing a salt of morphine.
NZ508526A (en) Opioid formulations for treating pain
YU48583B (sh) Postupak za pripremanje formulacije u obliku pilule za oralno davanje
CA2098738A1 (fr) Compositions d'oxycodone a degagement progressif
CA2264852A1 (fr) Utilisation de methylphenidate ou d'un sel pharmaceutique acceptable correspondant
CA2105165A1 (fr) Forme pharmaceutique pour l'administration de medicaments a liberation prolongee
NZ229518A (en) Pharmaceutical dosage form for the medication of fish: method of administration and (prophylactic) treatment
GEP19991686B (en) Pharmaceutical Composition for Obtaining Effervescent Powder or Tablet, Pharmaceutical Preparation and Method for Preparing Same
GEP20002229B (en) Synthetic Membrane Vesicles, Method for Obtaining and Application of the Same
AU2223095A (en) Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules
EP0866656A4 (fr) Inhibition du facteur alpha de necrose tumorale
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
MY124465A (en) Reduction of infarct volume using citicoline
ES2026304A6 (es) Procedimiento de fabricacion de una forma de dosificacion de nicardipina.
WO1997025049A1 (fr) Composition contenant de la diosgenine
EP0409893A4 (en) Magnetically influenced homeopathic pharmaceutical formulations, methods of their preparation and methods of their administration
HUP9900521A2 (hu) Eljárás nagyon kis dózisú hatóanyagok szilárd dózisformáinak előállítására
GB2121277A (en) Preparations for combating colds and flu, containing iron salt and calcium lactate
MY114610A (en) Controlled drug delivery system for diltiazem.
MY110769A (en) Controlled release oxycodone compositions.
SI0859595T1 (en) Therapeutic preparation for the transdermal administration of active substances
AU5912794A (en) Method and compositions for noninvasive dose to effect administration of lipophilic drugs
AU1470697A (en) Method and compositions for noninvasive dose to effect administration of lipophilic drugs
RU95120783A (ru) Способ профилактики и лечения атеросклероза